PHENOXYBENZAMINE HYDROCHLORIDE

PHENOXYBENZAMINE HYDROCHLORIDE was reported 27 times

PHENOXYBENZAMINE HYDROCHLORIDE is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CATASTROPHIC REACTION 2 0.0317
1 THERAPEUTIC AGENT-DIAGNOSTIC TEST INTERACTION 1 0.0217
2 ADRENERGIC SYNDROME 1 0.0123
3 PSEUDODEMENTIA 1 0.0084
4 PARAGANGLION NEOPLASM 1 0.0068
5 CARCINOID CRISIS 1 0.0044
6 VAGINAL CANCER 1 0.0031
7 PATIENT-DEVICE INCOMPATIBILITY 2 0.0029
8 INFUSION SITE MASS 2 0.0018
9 TUMOUR RUPTURE 1 0.0018
10 INFUSION SITE INDURATION 2 0.0013
11 BRADYCARDIA FOETAL 1 0.0012
12 BREAST ABSCESS 1 0.0010
13 HYPOPERFUSION 1 0.0010
14 HYPERKINESIA 2 0.0009
15 ORCHITIS 1 0.0009
16 RIGHT VENTRICULAR DYSFUNCTION 1 0.0009
17 EPIDIDYMITIS 1 0.0009
18 VASOPLEGIA SYNDROME 1 0.0006
19 BLOOD PH DECREASED 1 0.0006
20 ALOPECIA AREATA 1 0.0006
21 MICROCYTIC ANAEMIA 1 0.0005
22 ATRIAL TACHYCARDIA 1 0.0005
23 CALCINOSIS 1 0.0004
24 BLOOD LOSS ANAEMIA 1 0.0004
25 VITREOUS HAEMORRHAGE 1 0.0004
26 ON AND OFF PHENOMENON 2 0.0004
27 MICTURITION DISORDER 1 0.0003
28 HYPOPNOEA 1 0.0003
29 PROTEIN TOTAL DECREASED 1 0.0003
30 AZOTAEMIA 1 0.0003
31 BLOOD PRESSURE SYSTOLIC DECREASED 1 0.0002
32 ISCHAEMIA 1 0.0002
33 BLOOD PRESSURE DIASTOLIC INCREASED 1 0.0002
34 HAEMORRHOIDAL HAEMORRHAGE 1 0.0002
35 BLOOD LACTIC ACID INCREASED 1 0.0002
36 INTENTIONAL UNDERDOSE 1 0.0001
37 HAEMODYNAMIC INSTABILITY 1 0.0001
38 MATERNAL DRUGS AFFECTING FOETUS 1 0.0001
39 TRICUSPID VALVE INCOMPETENCE 1 0.0001
40 DEVICE USE ISSUE 2 0.0001
41 HIDRADENITIS 1 0.0001
42 SUPRAVENTRICULAR TACHYCARDIA 1 0.0001
43 FEEDING DISORDER 2 0.0001
44 NERVE INJURY 1 0.0001
45 CAESAREAN SECTION 1 0.0001
46 POLYNEUROPATHY 1 0.0001
47 DIALYSIS 1 0.0001
48 CARDIOGENIC SHOCK 1 0.0001
49 CYSTITIS 2 0.0001
50 CIRCULATORY COLLAPSE 1 0.0001
51 DELIRIUM 2 0.0001
52 METASTASES TO LIVER 1 0.0001
53 RESTLESSNESS 2 0.0001
54 BLOOD PRESSURE SYSTOLIC INCREASED 1 0.0001
55 HAEMATOCRIT DECREASED 1 0.0001
56 PRODUCT ADMINISTRATION ERROR 1 0.0000
57 HALLUCINATION, VISUAL 1 0.0000
58 BLOOD PRESSURE DECREASED 3 0.0000
59 PRODUCT AVAILABILITY ISSUE 1 0.0000
60 MENTAL IMPAIRMENT 1 0.0000
61 MENTAL STATUS CHANGES 1 0.0000
62 URINARY TRACT INFECTION 6 0.0000
63 ANGINA PECTORIS 1 0.0000
64 ACUTE MYOCARDIAL INFARCTION 1 0.0000
65 PREMATURE BABY 1 0.0000
66 CORONARY ARTERY DISEASE 1 0.0000
67 HYPOTHYROIDISM 1 0.0000
68 LACTIC ACIDOSIS 1 0.0000
69 LYMPHADENOPATHY 1 0.0000
70 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 2 0.0000
71 MOBILITY DECREASED 2 0.0000
72 ELECTROCARDIOGRAM QT PROLONGED 1 0.0000
73 DYSURIA 1 0.0000
74 INFLUENZA 3 0.0000
75 HALLUCINATION 2 0.0000
76 DEPRESSED LEVEL OF CONSCIOUSNESS 1 0.0000
77 DISORIENTATION 1 0.0000
78 MUSCULOSKELETAL STIFFNESS 2 0.0000
79 COVID-19 4 0.0000
80 BRADYCARDIA 1 0.0000
81 OXYGEN SATURATION DECREASED 1 0.0000
82 THERAPEUTIC RESPONSE DECREASED 1 0.0000
83 VISUAL IMPAIRMENT 2 0.0000
84 DEHYDRATION 2 0.0000
85 HEPATIC ENZYME INCREASED 1 0.0000
86 MULTIPLE SCLEROSIS RELAPSE 1 0.0000
87 AGITATION 1 0.0000
88 EPISTAXIS 1 0.0000
89 FOETAL EXPOSURE DURING PREGNANCY 1 0.0000
90 CARDIAC ARREST 1 0.0000
91 DRUG WITHDRAWAL SYNDROME 1 0.0000
92 MUSCLE SPASMS 2 0.0000
93 OROPHARYNGEAL PAIN 1 0.0000
94 HEART RATE INCREASED 1 0.0000
95 SYNCOPE 1 0.0000
96 FLUSHING 1 0.0000
97 MALIGNANT NEOPLASM PROGRESSION 1 0.0000
98 HAEMOGLOBIN DECREASED 1 0.0000
99 HYPERTENSION 2 0.0000
100 CONSTIPATION 2 0.0000
101 PALPITATIONS 1 0.0000
102 LOSS OF CONSCIOUSNESS 1 0.0000
103 VISION BLURRED 1 0.0000
104 MEMORY IMPAIRMENT 1 0.0000
105 WEIGHT DECREASED 2 0.0000
106 DRUG INTERACTION 1 0.0000
107 CONFUSIONAL STATE 1 0.0000
108 PNEUMONIA 2 0.0000
109 DIZZINESS 3 0.0000
110 ANAEMIA 1 0.0000
111 ALOPECIA 1 0.0000
112 SOMNOLENCE 1 0.0000
113 HEADACHE 3 0.0000
114 DIARRHOEA 3 0.0000
115 DEPRESSION 1 0.0000
116 DECREASED APPETITE 1 0.0000
117 ABDOMINAL PAIN 1 0.0000
118 INSOMNIA 1 0.0000
119 FALL 1 0.0000
120 FATIGUE 2 0.0000
121 VOMITING 1 0.0000
122 NAUSEA 1 0.0000
123 OFF LABEL USE 1 0.0000